Shots:

• Bluebird Bio to utilize its mRNA-based megaTAL technology providing a specific and efficient way to silence- edit or insert genetic components combining Novo Nordisk’s deep expertise in hemophilia research and therapeutics 
• The focus of the collaboration is to identify gene therapy candidates for people with severe genetic diseases with initial interest of correcting FVIII-clotting factor deficiency providing lifetime free of factor replacement therapy
• MegaTALs are single-chain fusion enzyme that combines to DNA cleaving processes of Homing Endonucleases (HEs) with the DNA binding region of transcription activator-like (TAL) effectors

Click here to­ read full press release/ article | Ref: Bluebird Bio | Image: Twitter